Brooklyn ImmunoTherapeutics (NYSE:BTX) Research Coverage Started at StockNews.com

Equities research analysts at StockNews.com started coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research report issued on Thursday. The brokerage set a “hold” rating on the stock.

Brooklyn ImmunoTherapeutics Stock Performance

Brooklyn ImmunoTherapeutics stock opened at $1.31 on Thursday. The stock has a fifty day moving average of $1.74 and a two-hundred day moving average of $1.96. The company has a market capitalization of $77.06 million, a price-to-earnings ratio of -0.58 and a beta of 4.61. Brooklyn ImmunoTherapeutics has a fifty-two week low of $0.17 and a fifty-two week high of $10.10.

About Brooklyn ImmunoTherapeutics

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.